908 Devices Inc. (NASDAQ: MASS) appointed Kola Otitoju as Chief Business & Strategy Officer, a newly created executive position. The company also announced an inducement grant under Nasdaq listing rules.

Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as the handheld chemical analysis device maker expands its market presence.

The executive brings over 25 years of leadership experience in strategy, business development, and profit and loss management across medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of Strategy & Business Development at Repligen Corporation, where he led global corporate strategy and executed more than 15 M&A transactions and strategic partnerships over six years.

Prior to Repligen, Otitoju held senior strategy and business development roles at Candela Medical, Baxter International, and GE Healthcare. He also spent eight years in investment banking at Credit Suisse and Bank of America Securities. He holds an MBA from Harvard Business School and engineering degrees from Cornell University and Imperial College, London.

On April 21, 2026, 908 Devices' Compensation Committee granted Otitoju 110,193 restricted stock units and options to purchase 146,789 shares as a material inducement to his employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest equally over three years starting May 1, 2027. The stock options have an exercise price of $7.26 per share, equal to the closing price on the grant date, and vest over three years with one-third vesting on May 1, 2027.

908 Devices manufactures handheld devices for chemical analysis used in health, safety, and defense applications, including addressing the fentanyl crisis and toxic exposure detection.